Torrent Pharmaceuticals' latest updates

Torrent Pharmaceuticals has declared a final dividend of ₹6.0 per share with today, June 20, 2025, as the record date. This follows a strong performance in Q4 FY25, where the company reported an 11% rise in consolidated net profit to ₹498 crore, primarily driven by its robust India business. For the full FY25, Torrent Pharma recorded a 15.4% growth in net profit. Revenue for Q4 FY25 grew by 8% year-on-year to ₹2,959 crore, with operating EBITDA increasing by 9% to ₹964 crore. In terms of strategic moves, Torrent Pharma is actively pursuing acquisitions to expand its portfolio and market presence. A notable recent acquisition, completed by March 2025, involved three anti-diabetes brands (Cospiaq, Cospiaq Met, and Xilingio) from Boehringer Ingelheim. This acquisition strengthens Torrent's position in the rapidly growing Indian diabetes medication market, especially in the SGLT-2 inhibitor segment. The company has also stated its ambition to break into the top three Indian drugmakers within five years, indicating a continued focus on strategic acquisitions and organic growth, particularly in the domestic market. Leadership changes are also underway, with Aman Mehta appointed as the Managing Director effective August 1, 2025, as part of the company's long-term succession planning. While the company's share price saw a slight dip recently, it has shown significant long-term growth. Torrent Pharma continues to focus on strengthening its presence in key international markets like the US, Germany, and Brazil, with new product launches and tender wins contributing to its global expansion strategy.